Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management

The importance of prostate-specific membrane antigen (PSMA) PET/CT for primary staging of treatment-naïve prostate cancer patients is still under debate. Therefore, the present study aimed to evaluate the role of PSMA PET/CT in detecting nodal metastases in a large cohort of men and compare imaging results with the risk of lymph node involvement based on the Roach formula. Methods: In total, 280 men with newly diagnosed prostate carcinoma were included in the present study. For all patients, PSMA PET/CT was performed for primary staging. Median age was 67 y (range, 38–84 y), and 84% of all patients were classified as high-risk according to the d’Amico criteria. The risk of lymph node involvement was calculated using the Roach formula and compared with the PSMA PET/CT results. Results: PSMA-positive nodes were detected in 90 of 280 men (32.1%). Although most nodal metastases occurred within the pelvis, 36.0% were in extrapelvic sites. In 9 patients (3.2%), nodal metastases occurred in the Virchow node. After comparison of PSMA data with the results of the Roach formula, an area under the curve of 0.781 was obtained for the Roach predictions. Conclusion: For treatment-naïve prostate cancer patients, PSMA PET/CT is well suited for the detection of nodal metastases. However, the original Roach formula can still be used for a quick assessment of potential lymphatic spread in daily clinical routine.

[1]  Adam P Dicker,et al.  Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[2]  T. Holland-Letz,et al.  68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients , 2018, The Journal of Nuclear Medicine.

[3]  K. Pienta,et al.  A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted 18F-DCFPyL Positron Emission Tomography Imaging , 2018, Urology.

[4]  P. Scalchi,et al.  Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial , 2018, Prostate Cancer and Prostatic Diseases.

[5]  J. Denham,et al.  Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning. , 2017, International journal of radiation oncology, biology, physics.

[6]  F. Montorsi,et al.  Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. , 2017, European urology.

[7]  K. Kopka,et al.  Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer , 2017, Pharmaceuticals.

[8]  Steven P Rowe,et al.  Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy , 2017, The Journal of Nuclear Medicine.

[9]  Steven P. Rowe,et al.  PSMA Ligands for PET Imaging of Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[10]  T. Holland-Letz,et al.  68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[11]  Tim Holland-Letz,et al.  Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study , 2017, The Journal of Nuclear Medicine.

[12]  D. Pérol,et al.  Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study. , 2016, International journal of radiation oncology, biology, physics.

[13]  C. Stief,et al.  68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. , 2016, European urology.

[14]  C. Fiorino,et al.  Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[15]  A. Buck,et al.  68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT , 2016, Clinical nuclear medicine.

[16]  M. Schwaiger,et al.  Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. , 2016, The Journal of urology.

[17]  A. Paul,et al.  Do prostate cancer nomograms give accurate information when applied to European patients? , 2015, Scandinavian journal of urology.

[18]  U. Haberkorn,et al.  Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer , 2014, Pharmaceuticals.

[19]  B. Trock,et al.  An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011 , 2013, BJU international.

[20]  U. Capitanio,et al.  Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. , 2012, European urology.

[21]  S. Williams,et al.  Predicting pelvic lymph node involvement in current-era prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[22]  U. Capitanio,et al.  Lymphatic spread of nodal metastases in high‐risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum , 2012, The Prostate.

[23]  Rakesh R. Patel,et al.  Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[24]  M. Balducci,et al.  Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy. , 2011, International journal of radiation oncology, biology, physics.

[25]  M. Mackenzie,et al.  Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[26]  A. D'Amico,et al.  Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. , 2009, International journal of radiation oncology, biology, physics.

[27]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[28]  P. Carroll,et al.  Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.